Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01807546 · ClinicalTrials.gov registry record · Phase 2
Oral Rigosertib for Squamous Cell Carcinoma
A Phase 2 study, sponsored by Traws Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT01807546 is a Phase 2 study that has completed, run by Traws Pharma. The registered enrollment target is 64 participants.
The verdict
NCT01807546, a Phase 2 study, has completed, sponsored by Traws Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following treatment with the investigational drug, rigosertib sodium (ON 01910.Na). A secondary objective is to determine if treatment with rigosertib causes any side effects. Rigosertib is an investigational drug, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) to treat any diseases. We are studying rigosertib as a new anticancer drug. Tests that we have done in the laboratory suggest that rigosertib works by blocking cell division in cancer cells and causing them to die.
Interventions
- DRUG rigosertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-03 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01807546
The ClinicalTrials.gov registry entry for NCT01807546 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Traws Pharma, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rigosertib is the first listed.
NCT01807546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01807546 about?
NCT01807546 is a clinical study titled "Oral Rigosertib for Squamous Cell Carcinoma". The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following treatment with the investigational drug, rigosertib sodium (ON 01910.Na)....
What is the current status of trial NCT01807546?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2013-03. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01807546?
The interventions under investigation include: rigosertib (DRUG).
Who is sponsoring clinical trial NCT01807546?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.